BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li W, Liu J, Cai J, Zhang XJ, Zhang P, She ZG, Chen S, Li H. NAFLD as a continuous driver in the whole spectrum of vascular disease. J Mol Cell Cardiol 2021;163:118-32. [PMID: 34737121 DOI: 10.1016/j.yjmcc.2021.10.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu X, Fan J, Ma Q, Han L, Cao Z, Xu C, Luan J, Jing G, Nan Y, Wu T, Zhang Y, Wang H, Zhang Y, Ju D. A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease. J Nanobiotechnology 2022;20:237. [PMID: 35590366 DOI: 10.1186/s12951-022-01456-z] [Reference Citation Analysis]
2 Čertíková Chábová V, Zakiyanov O. Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes. Int J Mol Sci 2022;23:2812. [PMID: 35269954 DOI: 10.3390/ijms23052812] [Reference Citation Analysis]